SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

A decent increase of about 41.22% in the sales to Rs. 3817.30 millions was observed for the quarter ended March 2024. The sales figure stood at Rs. 2703.00 millions during the year-ago period.The Total revenue for the quarter ended March 2024 of  Rs. 3495.88  millions  grew by 1061.61% from Rs. 300.95 millions.OP of the company witnessed a marginal growth to 977.57 millions from 707.96 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 3817.30 2703.00 41.22 12273.18 11519.57 6.54 12273.18 11519.57 6.54
Other Income 252.50 73.97 241.35 453.14 332.82 36.15 453.14 332.82 36.15
PBIDT 977.57 707.96 38.08 2952.81 2553.74 15.63 2952.81 2553.74 15.63
Interest -114.80 211.38 -154.31 510.96 921.66 -44.56 510.96 921.66 -44.56
PBDT 4958.27 496.58 898.48 6307.75 1365.60 361.90 6307.75 1365.60 361.90
Depreciation 126.74 131.88 -3.90 533.03 573.62 -7.08 533.03 573.62 -7.08
PBT 4831.53 364.70 1224.80 5774.72 791.98 629.15 5774.72 791.98 629.15
TAX 1335.65 63.75 1995.14 1590.81 367.25 333.17 1590.81 367.25 333.17
Deferred Tax -108.43 0.00 0.00 -108.43 233.61 -146.41 -108.43 233.61 -146.41
PAT 3495.88 300.95 1061.61 4183.91 424.73 885.08 4183.91 424.73 885.08
Equity 590.87 590.87 0.00 590.87 590.87 0.00 590.87 590.87 0.00
PBIDTM(%) 25.61 26.19 -2.22 24.06 22.17 8.53 24.06 22.17 8.53

Ind-Swift Lab. Share Price

137.05 -0.95 (-0.69%)
11-May-2026 09:41 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1845.50
Dr. Reddys Lab 1275.65
Cipla 1335.25
Zydus Lifesciences 930.20
Lupin 2257.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×